Barclays now sees two Fed cuts this year, says jumbo Fed cuts ’very unlikely’
In a recent transaction, Mark Plavsic, the Chief Technology Officer of Aura Biosciences , Inc. (NASDAQ:AURA), sold 2,151 shares of the company’s common stock. The shares were sold at a price of $7.75 each, totaling $16,670. The stock currently trades at $7.65, with analysts setting price targets between $20-23, suggesting significant upside potential. InvestingPro analysis shows the company maintains a strong liquidity position with a current ratio of 12.47. This sale was not discretionary but was conducted to cover tax withholding obligations associated with the vesting of restricted stock units. Following this transaction, Plavsic holds 209,456 shares of Aura Biosciences. InvestingPro data reveals the company holds more cash than debt, though it’s currently burning through cash reserves. Get access to 6 more key ProTips and comprehensive financial metrics with InvestingPro.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.